Euclises Pharmaceuticals
Business Services · Missouri, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4340 Duncan Ave Ste 240, St. Louis, Miss...Phone Number
(314) 932-4032Website
www.euclises.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Euclises Pharmaceuticals
Euclises Pharmaceuticals, Inc. is a biopharmaceutical company advancing novel cyclooxygenase-2 (COX-2) inhibitors (EuclicoxibsTM) for use in the treatment of cancer. Working with development partner Guangzhou Institute of Biomedicine and Health (GIBH), Euclises has selected a clinical development candidate (ECP-1014) and is currently conducting studies in preparation for human clinical trials. The company is headquartered within the BioGenerator Labs at CORTEX and supported by funding from Cultivation Capital, BioGenerator, Missouri Technology Corporation, the iSelect Fund, the St. Louis Arch Angels and other investors.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Euclises Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Euclises Pharmaceuticals had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Euclises Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Euclises Pharmaceuticals recently announced quarterly report
Check out if Euclises Pharmaceuticals is spiking on competitors!
Funding: Get notified immidiatlly once Euclises Pharmaceuticals has new funding data
Congratulate Masked Content for being promoted to Masked Content at Euclises Pharmaceuticals
Product Launch: Get notified when Euclises Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Euclises Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Euclises Pharmaceuticals
Compare insights from companies similar to Euclises Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Euclises Pharmaceuticals
<$5M
11-50
Private
<$5M
2011
N/A
Company Profile Activity
Activity Insights
Euclises Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Euclises Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Euclises Pharmaceuticals.
Euclises Pharmaceuticals financials insights
Gather financial insights about Euclises Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Private Equity
$174K
2013
Private Equity
$1.9M
2015
Private Equity
$1.2M
Euclises Pharmaceuticals Tech Stack
A closer look at the technologies used by Euclises Pharmaceuticals
See more technologies
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Euclises Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Euclises Pharmaceuticals, Inc. is a biopharmaceutical company advancing novel cyclooxygenase-2 (COX-2) inhibitors (EuclicoxibsTM) for use in the treatment of cancer. Working with development partner Guangzhou Institute of Biomedicine and Health (GIBH), Euclises has selected a clinical development candidate (ECP-1014) and is currently conducting stu... Read More
